Beneficial effects of phytochemicals in diabetic retinopathy: experimental and clinical evidence

S. OJHA1, V. BALAJI1, B. SADEK1, M. RAJESH1

1Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, Abu Dhabi, United Arab Emirates

Abstract. – Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and a major preventable cause of blindness. Strict control of blood glucose, blood pressure, and lipid profiles are the pivotal criteria to reduce the risk of developing DR. Although timely intervention with laser photoagulation therapy could mitigate the progression of DR, it may not significantly improve visual acuity. Therefore, invasive surgical interventions such as vitrectomy are sometimes the only option to treat or manage advanced stages of DR. However, the risk of intraocular infections outweighs the benefits of the surgery. Newer therapies such as intraocular injection of anti-vascular endothelial growth factor (VEGF) antibody and steroids serve as a viable option for the treatment of DR. However, several clinical studies that assessed the long-term efficacy and safety of this therapy have yielded inconclusive results. Therefore, there is an urgent need to develop potent and safe drugs for the effective management of DR. In this review, we discuss various plant-derived small molecules (phytochemicals) that have been investigated for retinal cytoprotective effects in pre-clinical and clinical studies. Furthermore, we highlight the caveats on using phytochemicals for the management of DR.

Key Words: Diabetes, Diabetic complications, Retinopathy, Phytochemicals, Inflammation, Oxidative stress.

Abbreviations

8-OHdG, 8-hydroxy-2-deoxyguanosine; ACE, Angiotensin-converting enzyme; AGEs, Advanced glycation end products; AR, Aldose reductase; BDNF, Brain-derived neurotrophic factor; BRB, Blood retinal barrier; Brn3a, A transcription factor specifically expressed in cells of the developing mammalian nervous system; DR, Diabetic retinopathy; eNOS, Endothelial NOS; ERK, Extracellular signal-regulated kinases; FAK, Focal adhesion kinase; GABA, Gamma-aminobutyric acid; GFAP, Glial fibrillary acidic protein; GLAST, Glutamate transporters; GS, Glutamine synthetase; GSH, Glutathione; HbA1C, Glycosylated hemoglobin; HIF-1α, Hypoxia-inducible factor-1α; ICAM-1, Intercellular adhesion molecule-1; IL, Interleukin; iNOS, Inducible NOS; MAPK, Mitogen-activated protein kinases; MDA, Malondialdehyde; MMP, Matrix metalloproteinases; MnSOD, Manganese superoxide dismutase; NOS, Nitric oxide synthase; NPDR, Non-proliferative diabetic retinopathy; NR1, N-methyl-D-aspartate receptor subunit 1; ops, Oscillatory potentials; PDR, Proliferative diabetic retinopathy; RGC, Retinal ganglion cells; ROS, Reactive oxygen species; RSA, Rat serum albumin; Thy-1, A surface glycoprotein of the immunoglobulin superfamily; specifically expressed in RGC; TNF-α, Tumor necrosis factor-α; VEGF, Vascular endothelial growth factor; WNIN, An inbred Wistar rat strain from National Institute of Nutrition Hyderabad, India.

Introduction

Diabetes mellitus has become a worldwide epidemic with a major impact on morbidity and mortality through the microvascular complications of blindness (retinopathy), end-stage renal disease (nephropathy), nerve damage (neuropathy) and lower extremity amputation (ischemic vasculopathy/peripheral artery disease) and macrovascular complications such as cardiovascular disease and stroke1. Since these complications pose a major socio-economic burden, it is crucial to understand the mechanisms of how the disease progresses, to devise comprehensive guidelines for early detection and management of diabetes, and to prevent the onset of these debilitating complications. Diabetic retinopathy (DR) is one of the most common diabetic complications, and is the leading cause globally of...
acquired blindness. Clinical and epidemiological studies indicate that 5-7% of patients with type-2 diabetes mellitus could develop DR2. Notwithstanding the improved health care and increased lifespan of mankind, the epidemic prevalence of obesity and diabetes, and the occurrence of cardiovascular complications is projected to rise at alarming rates2. Currently, there are no approved pharmacological interventions available to treat DR. Although surgical intervention could impede visual loss, it may also cause post-operative complications such as endophthalmitis, and thus, is often not recommended in practice1. By understanding the biochemical mechanisms underlying capillary loss, the major process involved in DR, precise pharmacological targets could be defined and used in future treatment strategies3,4.

Our knowledge about the pathological mechanisms underlying the development of DR is constantly expanding with new inputs from basic and clinical research. Chronic hyperglycemia and other risk factors such as hypertension and hyperlipidemia are thought to initiate a myriad of biochemical and physiological changes, which ultimately promote microvascular damages and retinal dysfunction. Several biochemical alterations in the diabetic milieu culminate the loss of retinal cells, and multiple abnormalities have been proposed to explain how hyperglycemia might cause the progression of retinopathy. For example, increased retinal neural and endothelial cells have been observed in an animal model with some confirmatory observations in human diabetes. Some of the pathways implicated in the development of retinopathy are due to an augmented polyol pathway, protein kinase C (PKC) activation, accumulation of advanced glycation end products (AGEs), oxidative stress, activation of the hexosamine biosynthesis pathway, growth factors and endocannabinoids synthesis5-9.

The most striking features of DR are the vascular abnormalities that are observed during the fundus examination. The rate of retinal cell loss occurs insidiously in uncontrolled diabetes, and without a regenerative process, the sustained cell loss results in catastrophic retinal tissue damage10. To date, there are no diagnostic tools available for the early detection of ongoing cell death, which would aid in early clinical intervention to prevent the progression of human DR. Therefore, development of novel cytoprotective agents that preserve the retinal neurovascular cells against hyperglycemia and its deleterious effects is of paramount significance for the efficient management of DR10. Medicinal plants have been used since ancient civilization for treating various ailments. In addition, plants contain diverse chemical constituents (phytochemicals) and they are being extensively investigated for their therapeutic potentials against various diseases affecting mankind11. In this review, we discuss the phytochemicals that have been investigated for their ability to ameliorate diabetes-induced retinal tissue injury.

**Phytochemicals Investigated for Retinal tissue Cytoprotective Effects in Rodent Models of DR**

The chemical structures for phytochemicals that were investigated for their ability to prevent diabetes-induced retinal tissues injury are illustrated in Figure 1. Next, the summary of effects observed when phytochemicals were administered in various rodent models of DR is presented in Table I.

**Anthocyanins**

Anthocyanins are a type of flavonoids12 and they have been reported to possess several health benefits13. Anthocyanins isolated from *Vaccinium myrtillus* mitigated diabetes-induced blood-retinal barrier breakdown by suppressing vascular endothelial growth factor (VEGF) production and attenuated the loss of tight junction proteins such as zonula occludens-1, occluding, and claudin-514. Similarly, blueberry anthocyanins also inhibited blood-retinal barrier breakdown by suppressing oxidative stress via activation of the Nrf2/HO-1 antioxidant defense system and by down-regulation of pro-inflammatory cytokine and VEGF expression15.

**Arctiin**

Arctiin is a lignan extracted from the fruits of *Arctium lappa*16 and are reported to improve whole body metabolism in rodents17. Recently, it was demonstrated that subjecting diabetic animals to treatment with arctiin significantly decreased retinal edema and retinal detachment, which corresponded to diminished VEGF expression in the retina. Furthermore, arctiin was shown to decrease high glucose-induced proliferation of retinal microvascular endothelial cells *in vitro*17. However, the precise molecular mechanisms underlying the beneficial effects of arctiin in preventing diabetes-induced retinal tissue injury are unknown.
Phytochemicals in diabetic retinopathy

Astaxanthin

Astaxanthin is the oxidized ketocarotenoid form of β-carotene, a common pigment extracted mainly from the crustacean family, such as shrimp, crawfish, crabs, and lobsters. Astaxanthin has been shown to possess antioxidant and anti-inflammatory properties and long-term supplementation is associated with a reduced risk for the development of cardiovascular diseases.

Astaxanthin was able to ameliorate diabetes-induced retinal tissue injury via attenuation of oxidative stress and augmentation of anti-apoptotic pathways. Furthermore, astaxanthin inhibited hydrogen peroxide-induced cell death and improved mitochondrial respiration in retinal ganglia cells exposed to high glucose. However, the precise biochemical cascade for astaxanthin cytoprotective is unknown.

Figure 1. Chemical structures of phytochemicals evaluated for their beneficial effects in thwarting diabetes-induced retinal tissue injury.
Table I. Comparison among HAMD, NIM and BI ratings.

<table>
<thead>
<tr>
<th>Phytochemical</th>
<th>Dose &amp; duration of treatment</th>
<th>Animal model</th>
<th>Effects observed</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthocyanins (Vaccinium myrtillus</td>
<td>100 mg.kg⁻¹.day⁻¹ Oral dose,</td>
<td>STZ-induced Brown</td>
<td>↓ VEGF Prevented the loss of tight junction proteins</td>
<td>14</td>
</tr>
<tr>
<td>extract)</td>
<td>6 weeks</td>
<td>Norway (BN) rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arctiin (Arctium lappa L.)</td>
<td>30, 90, 270 mg.kg⁻¹.day⁻¹</td>
<td>STZ-induced</td>
<td>↓ HbAIC, VEGF Improved retinal edema, retinal</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Intra gastric (IG) dose,</td>
<td>Sprague Dawley (SD)</td>
<td>detachment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16 weeks</td>
<td>rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Astaxanthin (carotenoids present</td>
<td>25, 50 mg.kg⁻¹.day⁻¹ Oral</td>
<td>db/db mice</td>
<td>↓ Oscillatory potentials (Ops), Oxidative stress,</td>
<td>20</td>
</tr>
<tr>
<td>in plants, algae and seafood)</td>
<td>dose, 8 weeks</td>
<td></td>
<td>↓ apoptosis of retinal ganglion cells (RGC)</td>
<td></td>
</tr>
<tr>
<td>Baicalein (Scutellaria baicalensis)</td>
<td>150 mg.kg⁻¹ Oral dose,</td>
<td>STZ-induced SD rats</td>
<td>↓ GFAP, VEGF, IL-18, TNF-α, IL-1β</td>
<td>23</td>
</tr>
<tr>
<td>Betaine (capsicum, silybum, Beta</td>
<td>250, 500 mg.kg⁻¹.day⁻¹ Oral</td>
<td>STZ-induced SD rats</td>
<td>↓ VEGF, HIF-1α, Akt</td>
<td>25</td>
</tr>
<tr>
<td>vulgaris)</td>
<td>dose, 14 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabidiol (Cannabis sativa)</td>
<td>10 mg.kg⁻¹ every 2 days,</td>
<td>STZ-induced SD rats</td>
<td>↓ ROS, TNF-α, VEGF, BRB breakdown Inhibition of p38</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Intra peritoneally (IP), 4</td>
<td></td>
<td>MAPK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carotenoids (β-carotene)</td>
<td>10 mg.kg⁻¹ IP, 14 days</td>
<td>STZ-induced SD rats</td>
<td>↓ Oxidative stress</td>
<td>37</td>
</tr>
<tr>
<td>Chlorogenic acid (ubiquitously</td>
<td>10 and 20 mg.kg⁻¹ day⁻¹ IP,</td>
<td>STZ-induced SD rats</td>
<td>↓ VEGF, BRB breakdown ↑ Occludin, claudin-5, and ZO-1</td>
<td>46</td>
</tr>
<tr>
<td>present in plants)</td>
<td>14 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Curcumin (Curcuma longa)</td>
<td>0.05% fed with diet, 6 weeks</td>
<td>STZ-induced Lewis rats</td>
<td>↓ IL-1β, VEGF and NF-xB</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>0.002%, 0.01% fed with AIN-93</td>
<td>STZ-induced Wistar rats</td>
<td>↓ VEGF</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>diet, 8 weeks</td>
<td></td>
<td>↓ TNF-α, VEGF, prevented structural degeneration ↑</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>1 g. kg⁻¹ as Oral suspension,</td>
<td></td>
<td>Capillary basement membrane thickness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>80 mg.kg⁻¹ day⁻¹ IP, 3</td>
<td>STZ-induced SD rats</td>
<td>↓ MDA, GFAP</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>months</td>
<td></td>
<td>↑ GSH</td>
<td></td>
</tr>
<tr>
<td>Phytochemical</td>
<td>Dose &amp; duration of treatment</td>
<td>Animal model</td>
<td>Effects observed</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Dammarenediol-II (Panax ginseng)</td>
<td>25 µg Intravitreal injection, Single dose</td>
<td>STZ-induced C57BL/6j mice</td>
<td>↓ ROS, Stress fiber formation, ↓ Vascular endothelial-cadherin disruption</td>
<td>56</td>
</tr>
<tr>
<td>Epigallocatechin-3-gallate (Camellia sinensis)</td>
<td>20 and 40 mM</td>
<td>High glucose induced human retinal endothelial cell line</td>
<td>↓ MAPK, ERK1/2</td>
<td>60</td>
</tr>
<tr>
<td>Eriodictyol (Eriodictyon californicum)</td>
<td>0.1, 1 and 10 mg.kg⁻¹.day⁻¹ Oral dose, 10 days</td>
<td>STZ-induced SD rats</td>
<td>↓ LPO, ↓ VEGF, ICAM-1, and eNOS</td>
<td>63</td>
</tr>
<tr>
<td>Genistein (Glycine max)</td>
<td>0.25 mg.kg⁻¹.day⁻¹, Subcutaneous (SC), 12 weeks</td>
<td>STZ-induced Wistar rats</td>
<td>↓ TNFα, VEGF, iNOS</td>
<td>68</td>
</tr>
<tr>
<td>Hesperetin (citrus fruits)</td>
<td>200 mg.kg⁻¹.day⁻¹ Oral dose, 24 weeks</td>
<td>STZ-induced Wistar rats</td>
<td>↓ VEGF, PKC-β</td>
<td>71</td>
</tr>
<tr>
<td>Icariin (Epimedi Herba)</td>
<td>5 mg.kg⁻¹.day⁻¹ Oral dose, 12 weeks</td>
<td>STZ-induced SD rats</td>
<td>↑ Thy-1, Brn3a</td>
<td>74</td>
</tr>
<tr>
<td>Isolavones (Caesalpinia pulcherrima)</td>
<td>80, 160 mg.kg⁻¹.day⁻¹ Oral dose, 8 weeks</td>
<td>STZ-induced Wistar rats</td>
<td>↑ AR inhibition</td>
<td>76</td>
</tr>
<tr>
<td>Luteolin</td>
<td>25-100 mg.kg⁻¹.day⁻¹ Oral dose, 12 weeks</td>
<td>STZ-induced rats</td>
<td>↑ GSH, GPx, ↓ MDA, IL-1β, VEGF, NF-κB</td>
<td>78</td>
</tr>
<tr>
<td>Polyphenols (Cocoa, tea)</td>
<td>0.12, 2.9 or 22.9 mg.kg⁻¹.day⁻¹ Oral dose, 16 weeks</td>
<td>STZ-induced hypertensive male SHR</td>
<td>↓ ROS, PARP-1</td>
<td>83</td>
</tr>
<tr>
<td>Puerarin (Radix Puerariae)</td>
<td>80 mg.kg⁻¹.day⁻¹ IP, 6 doses, before and after STZ injection</td>
<td>STZ-induced Wistar rats</td>
<td>↑ VEGF, HIF-1α</td>
<td>86</td>
</tr>
<tr>
<td>Resveratrol (grapes and berries)</td>
<td>5 mg.kg⁻¹.day⁻¹ Oral dose, 4 months</td>
<td>STZ/ Nicotinamide-induced Wistar rats</td>
<td>↓ Oxidative stress, ↓ NFκB, apoptosis, Vessel leakage, pericyte loss, VEGF</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>20 mg.kg⁻¹.day⁻¹ Oral dose, 4 weeks</td>
<td>STZ-induced C57BL/6j mice</td>
<td>↓ VEGF, ACE, MMP-9, eNOS</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>10 mg.kg⁻¹.day⁻¹ IP, 4 weeks</td>
<td>STZ-induced Wistar rats</td>
<td>↓ NF-kB, TNF-α, apoptosis</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>5 mg.kg⁻¹.day⁻¹ Oral dose, 4 months</td>
<td>STZ/ Nicotinamide-induced Wistar rats</td>
<td>↑ GLAST, GS</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>5, 10 mg.kg⁻¹.day⁻¹ Oral dose, 1-7 months</td>
<td>STZ-induced SD rats</td>
<td>↑ GSH, BDNF, NGF</td>
<td>101</td>
</tr>
<tr>
<td>Rutin (onions, apples, tea and red wine)</td>
<td>100 mg.kg⁻¹.day⁻¹ Oral dose, 5 weeks</td>
<td>STZ-induced Wistar rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sesamin (Sesamum indicum)</td>
<td>30 mg.kg⁻¹ IP, alternative days, 4 weeks</td>
<td>STZ-induced C57BL/6j mice</td>
<td>↓ Microglia activation and TNF-α</td>
<td>103</td>
</tr>
<tr>
<td>Silybin (Silybum marianum)</td>
<td>15,30 mg.kg⁻¹.day⁻¹ Oral dose, 22 weeks</td>
<td>High fat diet, STZ-induced SD rats</td>
<td>↓ ICAM-1, iNOS, retinal vascular leukostasis</td>
<td>105</td>
</tr>
<tr>
<td>Troxerutin (Sophora japonica)</td>
<td>10, 50 mg.kg⁻¹.day⁻¹ Oral dose, 3 months</td>
<td>STZ-induced SD rats</td>
<td>↓ VEGF</td>
<td>107</td>
</tr>
</tbody>
</table>
Baicalein

Baicalein is a natural flavonoid isolated from *Scutellaria baicalensis*, a commonly used traditional Chinese herbal medicine and reported to elicit chemo-preventive actions. In diabetic-rodents, baicalein treatment, ameliorated microglial activation and pro-inflammatory expression. However, detailed mechanistic studies are warranted to understand the beneficial effects of baicalein in diabetic milieu.

Betaine

Betaine is a zwitterionic quaternary ammonium compound, widely distributed in several marine invertebrates, plants, and animals. In the liver, betaine plays a pivotal role in carbon metabolism by serving as a methyl group donor and detoxification of homocysteine. Betaine attenuated diabetes-induced vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF-1α) expression in retina. Paradoxically, there was significant Akt activation observed in the diabetic retinal tissues, which was suppressed by betaine. Therefore, additional studies are warranted to establish the precise molecular mechanism purported for betaine’s beneficial role in preventing diabetes-induced retinal tissue injury.

Cannabidiol (CBD)

CBD is the major non-psychotropic component *Cannabis sativa* and possesses antidepressant and anxiolytic properties. Treatment of CBD to diabetic animals was shown to reduce oxidative stress, tumor necrosis factor-alpha (TNF-α), vascular endothelial growth factor (VEGF), and intercellular adhesion molecule-1 (ICAM-1) expressions, and prevented retinal cell death and vascular hyperpermeability in retinal tissues. Furthermore, retinal protective effects of CBD were attributed to suppression of p38 MAP kinase in the diabetic retina. In addition, CBD has been demonstrated to ameliorate the development of diabetic cardiomyopathy via mitigation of oxidative stress, inflammation, and cell death pathways. Recently, a pilot clinical trial involving subjects with type 2 diabetes mellitus indicated that CBD improved insulin sensitivity and decreased biomarkers for metabolic dysfunction. Considering these findings, CBD has potential for future therapeutic utility to combat diabetic vascular complications.
**Carotenoids**

Dietary carotenoids provide health benefits by decreasing the risk for the development of cardiovascular diseases. In addition, owing to its strong antioxidant properties, it is widely used in nutraceuticals and cosmetic products. Sevin and Cuendet reported on the use of carotenoids to prevent capillary resistance in diabetes. Thereafter, several studies reported on the role of carotenoids in ameliorating DR. The dietary carotenoid zeaxanthin was found to inhibit diabetes-induced retinal oxidative damage and to prevent the elevation of VEGF and ICAM-1 levels. Lutein, another carotenoid, has been shown to decrease oxidative stress and lipid peroxidation (LPO) in diabetic retinal tissues. Furthermore, another carotenoid (lycopene) was reported to decrease diabetes-induced oxidative stress in retinal tissues.

**Chlorogenic Acid (CGA)**

Chlorogenic acid (5-caffeoylquinic acid) is a polyphenolic compound, present in coffee, tea, apples, peaches, carrots, blueberries, tomatoes, oilsseeds, eggplants, prunes, and cherries. Many studies have linked CGA consumption to a wide range of health benefits, including neuroprotection, cardioprotection, chemoprevention, anti-inflammatory activity, blood pressure control, decreased diet-induced insulin resistance, and anxiolytic effects. First, Shin et al reported on the role of CGA in preserving tight junction proteins, and to suppress VEGF production, resulting in the maintenance of blood–retinal barrier integrity. In addition, CGA inhibited VEGF-induced angiogenesis, mitigated AGE formation, and mitigated high-glucose induced oxidative stress and inflammation in the diabetic retinal tissues.

**Curcumin**

Curcumin is the sesquiterpene extracted from *Curcuma longa*. Curcumin has been shown to possess antioxidant, anti-inflammatory, and chemopreventive properties. Curcumin treatment to diabetic animals was found to improve antioxidant capacity, and inhibit diabetes-induced elevation of IL-1β, VEGF, and NF-κB activation in retinal tissues. Furthermore, curcumin also decreased pro-inflammatory cytokine expression and prevented structural degeneration and avascular capillary basement membrane thickening in diabetic retinas. In addition, curcumin inhibited diabetes-induced apoptosis of Müller cells, preventing the down-regulation of glutamine synthetase (GS), and decreased glial fibrillary acidic protein (GFAP) in diabetic retina.

**Dammarenediol-II**

Dammarenediol-II is a triterpene extracted from the popular medicinal plant *Panax ginseng*. Dammarenediol-II was found to inhibit VEGF-induced intracellular reactive oxygen species (ROS) generation, stress fiber formation, and vascular endothelial-cadherin disruption in human umbilical vein endothelial cells (HUVECs), and prevented microvascular leakage in the retina. However, the precise mechanism for dammarenediol-II’s retinal protective effect in the diabetic environment is not clear. Since HUVECs are derived from a macro vessel, they are not considered an appropriate model system to investigate the effect of hyperglycemia-induced alterations in the retinal microvasculature.

**Epigallocatechin-3-Gallate (EGCG)**

EGCG is a flavonoid found in variety of vegetable foods and beverages, such as fruits, chocolate, wine, tea, but mainly in green tea (*Camellia sinensis* L.), accounting for more than 50% of total green tea polyphenols and has great potential in cancer prevention. EGCG was shown to decrease extracellular regulated kinase (ERK)1/2 and inhibit VEGF and eNOS.

**Eriodictyol**

Eriodictyol, is a flavonoid extracted from North American plant *Eriodictyon californicum* and from Chinese herb *Dracocephalum rup-estre* and its glycoside, eriodictyol 7-O-rutinoside, is present in lemon fruit. Eriodictyol was demonstrated to protect retinal endothelial cells against high-glucose induced cell death and also attenuated β-amyloid peptide-induced oxidative stress-mediated cell death in retinal neurons. Furthermore, eriodictyol was found to inhibit the production of TNF-α, ICAM-1, VEGF, and eNOS in diabetic retinal tissues.

**Genistein**

Genistein (4’,5, 7-trihydroxyisoflavone) occurs as a glycoside in *Leguminosae* family plants, which includes the soybean (*Glycine max*). Genistein was found to inhibit retinal vascular leakage in experimentally induced diabetic rats. In addition, genistein combined with other polysaccharides improved the antioxidant status in diabetic retina. Furthermore, genistein attenuated...
Hesperetin (HST)
Hesperetin, a flavanone glycoside (a subclass of flavonoids), is found abundantly in citrus fruits. Kumar et al. have reported that HST was found to inhibit the expression of VEGF and PKC-β in diabetic retina. In addition, HST treatment suppressed diabetes-induced caspase-3 activation, glial activation, aquaporin-4 (AQP4) expression and retinal oxidative stress.

Icariin
Icariin (an 8-prenyl derivative of kaempferol 3,7-O-diglucoside) is the most abundant constituent and chosen as the chemical marker for quality control of Herba Epimedii in Chinese Pharmacopeia and has extensive clinical indications, especially for the treatment of sexual dysfunction and osteoporosis. Icariin was demonstrated to suppress the upregulation of rat endothelial cell antigen-1 (RECA), VEGF, and retinal ganglion cell-specific markers (Thy-1 and Brn3a) in the diabetic retina.

Isoflavones
Isoflavones belong to the “phytoestrogen” class, mainly found in soybeans, and legumes. Isoflavones isolated from Caesalpinia pulcherrima were shown to reduce oxidative stress and inhibit aldose reductase (AR) activity in the diabetic retinal tissues.

Luteolin
Luteolin is a natural flavonoid isolated from Platycodon grandiflorus which is widely used in Asian traditional herbal medicine and also found in dietary sources such as celery, broccoli, green pepper, parsley, thyme, dandelion, perilla, chamomile tea, carrots, olive oil, peppermint, rosemary, navel oranges, and oregano. Luteolin was shown to inhibit diabetes-induced elevation of IL-1β, VEGF, and NF-κB expression in the retina of diabetic rodents.

Polyphenols
Polyphenols constitute the active substances found in blackberries, red grapes, apricots, eggplants, and popular beverages, such as coffee, cocoa, and green tea. Polyphenols modulate the activity of a wide range of enzymes and cell receptors. Polyphenols from finger millet (Eleusine coracana) were found to inhibit AR and to prevent cataractogenesis. Polyphenols from red wine were shown to reduce retinal oxidative and nitrative stress. Polyphenols from green tea have been shown to decrease glial fibrillary acidic protein (GFAP) expression and oxidative stress in the retina. In addition, polyphenols from cocoa were also found to reduce oxidative stress, PARP activation, and augmented SIRT1 activity in diabetic retinas.

Puerarin
Puerarin (isoflavone-C-glucoside) is derived from Pueraria lobata root. In traditional Chinese medicine, it has been suggested to be useful in the treatment of cardiovascular and cerebrovascular diseases, diabetes mellitus and diabetic complications, osteonecrosis, Parkinson’s disease, Alzheimer’s disease, endometriosis, and cancer. First, Ren et al. have reported that puerarin improved the retinal microvascular rheology, and improved microcirculation in retinal tissues. Furthermore, puerarin was shown to down-regulate streptozotocin (STZ) induced-VEGF and HIF-1α in experimental DR. In addition, puerarin decreased the apoptosis of retinal pigment epithelium (RPE) cells in diabetic rats by reducing peroxynitrite levels and iNOS expression. Kim et al. have shown that, puerarin ameliorated retinal microvascular dysfunction, by inhibiting AGE-induced pericyte apoptosis by interfering with the NADPH oxidase-related ROS generation pathways and blocking NF-κB activation.

Resveratrol (RVT)
Resveratrol (3, 4’, 5-trihydroxystilbene) is a natural polyphenolic phytoalexin that is mainly found in grapes and fruit berries and reported to be useful in the treatment of neurodegenerative diseases, diabetes and cardiac ailments. RVT was found to suppress diabetes-induced oxidative stress, NF-κB activation, pro-inflammatory cytokines expression, and apoptosis in the retinal tissues. Furthermore, RVT treatment also prevented diabetes-induced neuronal cell death, vascular hyperpermeability, and basement membrane thickening. These effects were in part attributed to the diminution of ACE and MMP-9 expression and augmentation of eNOS. In addition, RVT also improved the retinal nerve function as assessed by electroretinogram (ERG).
Phytochemicals in diabetic retinopathy

Rutin
Rutin (3,30,40,5,7-pentahydroxyflavone-3-rhamnoglucoside) is a flavonoid found in many plants, such as buckwheat, passion flower, apple, and tea and possesses multi-spectrum pharmacological benefits for the treatment of various chronic diseases such as cancer, diabetes mellitus, hypertension, and hypercholesterolemia. Several studies have reported on the efficacy of rutin for eye diseases. Ola et al. have shown that providing rutin treatment to diabetic animals enhanced brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), suppressed pro-apoptotic pathways, and prevented neuronal apoptosis in retinal tissues.

Sesamin
Sesamin, an antioxidant lignan, is obtained from oilseed Sesamum indicum and is synthesized from shikimic acid via the phenylpropanoid pathway, then metabolized to enterolignans, which play a pivotal role in protection against several hormone-related diseases. Sesamin was found to inhibit the progression of diabetic retinal injury by suppressing pro-inflammatory cytokine expression and microglia activation. However, the precise molecular mechanism is not evident from this study.

Silybin
Silybin, a bioactive polyphenolic flavonoid extracted from milk thistle seeds (Silybum marianum), has been used as a traditional drug for over 2000 years to treat a range of liver diseases. Silybin was found to prevent the obliteration of retinal capillaries and retinal vascular leukostasis via suppression of ICAM-1 expression.

Troxerutin (TX)
Troxerutin (Vitamin P4) is a flavonoid best known for its radioprotective and antioxidant properties. Administration of TX to diabetic animals was found to attenuate oxidative stress and VEGF expression in the retina; however, detailed mechanistic studies were not performed and therefore further confirmatory studies are warranted to ascertain TX’s beneficial effects in the prevention of diabetes-induced retinal tissue injury.

Human Clinical Studies Undertaken to Investigate the Beneficial Effects of Phytochemical and or Herbal Extracts on the Progression of Diabetic Retinopathy
The various herbal extracts and phytochemicals that were investigated for their ability to thwart the development of DR are presented in Table II. A randomized double-blind clinical study assessed the efficacy of the Chinese herbal extract Salvia miltiorrhiza in subjects with non-proliferative DR (NPDR). Results suggested that Salvia miltiorrhiza treatment for 24 weeks prevented diabetes-induced alterations in the retinal anatomy. In a central African cohort, it was demonstrated that supplementation of herbal extracts had profound antioxidant augmenting effects in subjects with DR. However, the direct effect of herbal extract supplementation on various clinical endpoints for the amelioration of DR was not evident from this study. Similarly, other clinical trials also reported that supplementation with herbal extracts led to significantly positive outcomes pertaining to the clinical end points evaluated for progression of DR.

Limitations
Phytochemicals attenuated the development of DR in pre-clinical studies via suppression of oxidative stress, inflammation, and apoptosis pathways. Invariably, all studies have reported the apparent protective effects of phytochemicals against diabetes-induced retinal tissue injury in pre-clinical experiments and in human clinical trials. However, the major impediment to using phytochemicals for the management of DR is the lack of significant bioavailability in human subjects. In fact, a recent clinical trial revealed that RVT supplementation to subjects with type 2 diabetes mellitus suppressed the metformin/insulin sensitizing action owing to drug-drug interactions, and had no effect in improving hepatic glucose disposition or peripheral insulin sensitivity.

Conclusions
Before presenting phytochemicals as candidates for future drug development against DR, we should consider the potential drug-drug interactions, which could curtail the therapeutic action of these drugs. Although, clinical studies have been undertaken to establish the efficacy and safety of herbal extracts for the management of DR, these studies were seldom replicated in other locations. Also, the selectivity and specificity of phytochemical mode of actions and their molecular drug targets in DR is yet to be established, meaning that there is no surrogate...
marker available to assess the prognosis of DR. Furthermore, the pathophysiology of DR is not completely established and with the failure of anti-VEGF based therapy for DR\textsuperscript{117}, it is apparent that more basic clinical research is required. This research should identify early biomarkers for retinal tissue damage, and purported specific molecular/biochemical alterations, and attempt to use this information to develop new potent drugs for the efficient management of DR.

\textbf{Acknowledgments}

Bassem Sadek, Shreesh Ojha, and Mohanraj Rajesh are supported by intramural research grants sponsored by the Office of Graduate Studies and Research of United Arab Emirates University.

\textbf{Author contributions}

MR and SO conceptualized the review, searched the literature, drafted, edited, and prepared the final version of the manuscript. BV reviewed literature and drafted the manuscript. BS drew the chemical structures of phytochemicals.

\textbf{Conflict of interest}

The authors declare no conflicts of interest.

\textbf{References}

Phytochemicals in diabetic retinopathy


58) SINGH BN, SHANKAR S, SIRIVASTAVA RK. Green tea catechins, epigallocatechin-3-gallocatechin (EGCG):


73) Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba epimedii. Life Sci 2015; 126: 57-68.


